Medical technology company Stryker has agreed to acquire all issued and outstanding shares of Artelon, a privately held developer of soft tissue fixation products.

The strategic move aims to bolster Stryker’s offerings in the soft tissue fixation segment.

Stryker expects Artelon’s technologies to complement its existing range, offering more than 60,000 implantations worldwide.

The acquisition also complies with Stryker’s commitment to providing advanced solutions for ligament and tendon reconstruction.

The integration of Artelon’s synthetic technology is expected to enhance biological and mechanical ligament and tendon reconstruction, supporting patient healing and recovery.

Stryker trauma and extremities division president Tim Lanier said: “Artelon’s proven product portfolio and differentiated offerings will enhance our ability to innovate and serve our customers.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“The addition of Artelon’s products to our already robust foot and ankle and sports medicine product portfolios will fuel our goal of establishing comprehensive offerings for customers in these segments.

“We share a common dedication to integrity, quality, and advancing the knowledge of healthcare providers to achieve the best clinical outcomes and rebuild patients’ lives.”

Subject to customary closing conditions, both companies will maintain their separate operations until the deal’s completion.

Furthermore, Stryker expects the deal to help position itself more competitively in the foot and ankle and sports medicine segment with a biomaterial technology, which supports soft tissue healing for patients.

In May 2023, Stryker completed the acquisition of US-based commercial-stage medical device company Cerus Endovascular.

Cerus is involved in the design, development, manufacture and supply of interventional neurovascular devices and delivery systems for the treatment of intracranial aneurysms.

Neurovascular devices are used in the treatment of acute, life-threatening neurological conditions.